Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites
Status:
Completed
Trial end date:
2018-07-26
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and clinical benefit of MBN-101 administered intraoperatively
to osteosynthesis or osteomyelitis sites for patients diagnosed with an orthopedic infection,
with or without orthopaedic hardware. Three quarters of the patients will receive MBN-101,
while the other one quarter will receive placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Microbion Corporation
Collaborators:
Congressionally Directed Medical Research Programs Medpace, Inc. University of California, San Francisco University of Pennsylvania